Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00056459
Status:
COMPLETED
Last Update Posted:
2020-02-10
First Post:
2003-03-13
Brief Title:
Study of Oxaliplatin5-FULeucovorin Plus Vatalanib Versus Oxaliplatin5-FULeucovorin in Patients With Metastatic Colorectal Cancer
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin5-fluorouracilLeucovorin With PTK787ZK 222584 or Placebo
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare treatment with oxaliplatin5-FUleucovorin plus vatalanib versus oxaliplatin5-FUleucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CONFIRM 1 | None | None | None |